Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S
Third Department of Internal Medicine, Sapporo Medical University School of Medicine, Japan.
Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1860-6. doi: 10.1164/ajrccm.152.6.8520747.
Pulmonary surfactant protein D (SP-D) is a hydrophilic glycoprotein with a reduced molecular mass of 43 kDa and a member of the C-type lectin superfamily, along with mannose-binding proteins and surfactant protein A (SP-A). We have recently prepared monoclonal antibodies against human SP-D and developed an enzyme-linked immunosorbent assay (ELISA). In this study, the levels of SP-D in sera and bronchoalveolar lavage (BAL) fluids of patients with lung diseases were determined by ELISA, using human recombinant SP-D as a standard. We demonstrated that the concentrations of SP-D in sera are prominently increased in patients with idiopathic pulmonary fibrosis (IPF), interstitial pneumonia with collagen disease (IPCD), and pulmonary alveolar proteinosis (PAP). Patients with IPF, IPCD, and PAP exhibited levels of serum SP-D 5.1-fold, 7.2-fold, and 7.0-fold, respectively, of those in healthy volunteers; 91.5% of the patients with IPF, 81.3% with IPCD, and 100% with PAP exhibited serum SP-D levels that exceeded the cut-off value (mean + 2 SD of control value). Serum SP-D levels appeared to reflect the disease activity of IPF and IPCD and the disease severity of PAP. High levels of SP-D in BAL fluids were shown in patients with PAP, but not with IPF and IPCD. We conclude that measurement of SP-D in sera can provide an easily identifiable and useful clinical marker for the diagnosis of IPF, IPCD, and PAP, and can predict the disease activity of IPF and IPCD and the disease severity of PAP.
肺表面活性蛋白D(SP-D)是一种亲水糖蛋白,分子量约为43 kDa,是C型凝集素超家族的成员,与甘露糖结合蛋白和表面活性蛋白A(SP-A)同属该家族。我们最近制备了抗人SP-D的单克隆抗体,并开发了一种酶联免疫吸附测定法(ELISA)。在本研究中,以人重组SP-D为标准品,采用ELISA法测定了肺部疾病患者血清和支气管肺泡灌洗(BAL)液中的SP-D水平。我们发现,特发性肺纤维化(IPF)、胶原病相关性间质性肺炎(IPCD)和肺泡蛋白沉积症(PAP)患者血清中的SP-D浓度显著升高。IPF、IPCD和PAP患者血清中SP-D的水平分别是健康志愿者的5.1倍、7.2倍和7.0倍;91.5%的IPF患者、81.3%的IPCD患者和100%的PAP患者血清SP-D水平超过临界值(对照组均值+2标准差)。血清SP-D水平似乎反映了IPF和IPCD的疾病活动情况以及PAP的疾病严重程度。PAP患者的BAL液中SP-D水平较高,而IPF和IPCD患者则不然。我们得出结论,测定血清中的SP-D可为IPF、IPCD和PAP的诊断提供一种易于识别且有用的临床标志物,并可预测IPF和IPCD的疾病活动情况以及PAP的疾病严重程度。